> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Breakthrough Status for AngioVac System
- URL: https://www.fdaweb.com/breakthrough-status-for-angiovac-system/
- Published: 2023-08-15T12:00:00.000Z
- Updated: 2026-09-14T18:50:26.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5155108

FDA has granted AngioDynamics a breakthrough device designation for its AngioVac System and its proposed indication for use to include the non-surgical removal of vegetation (lesions) from the right side of the heart. The AngioVac System is described as an on-circuit aspiration system that uses a venous drainage cannula to remove thrombi or emboli during extracorporeal bypass for up to six hours. “The system allows for the removal of thrombus and embolic material while minimizing blood loss via a recirculation of blood through the AngioVac extracorporeal (venovenous) bypass circuit,” the company says.